350 related articles for article (PubMed ID: 8508371)
1. Combined carboplatin and cisplatin. Limited prospects for dose intensification.
Waterhouse DM; Reynolds RK; Natale RB
Cancer; 1993 Jun; 71(12):4060-6. PubMed ID: 8508371
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
Lund B; Hansen OP; Hansen HH; Hansen M
Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
[TBL] [Abstract][Full Text] [Related]
4. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
Fanning J; Hilgers RD
Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma.
Dittrich C; Sevelda P; Baur M; Marth C; Hudec M; Vavra N; Grunt T; Fazeny B; Salzer H
Cancer; 1993 May; 71(10):3082-90. PubMed ID: 8490836
[TBL] [Abstract][Full Text] [Related]
6. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.
Dittrich Ch; Sevelda P; Salzer H; Obermair A; Speiser P; Breitenecker G; Schemper M; Kaider A;
Eur J Cancer; 2003 May; 39(8):1129-40. PubMed ID: 12736113
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
8. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
9. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
[TBL] [Abstract][Full Text] [Related]
13. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC
Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657
[TBL] [Abstract][Full Text] [Related]
14. Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).
Lorusso V; Leone B; Di Vagno G; Manzione L; Palmeri S; Vallejo C; Machiavelli M; Nacci G; Bilancia D; Leonardi V; Catino A; Gargano G; Loverro G; Selvaggi L; De Lena M
Gynecol Oncol; 1998 Feb; 68(2):172-7. PubMed ID: 9514802
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
16. Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion.
Trump DL; Grem JL; Tutsch KD; Willson JK; Simon KJ; Alberti D; Storer B; Tormey DC
J Clin Oncol; 1987 Aug; 5(8):1281-9. PubMed ID: 3040920
[TBL] [Abstract][Full Text] [Related]
17. Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma.
Böhm S; Oriana S; Spatti G; Di Re F; Breasciani G; Pirovano C; Grosso I; Martini C; Caraceni A; Pilotti S; Zunino F
Oncology; 1999; 57(2):115-20. PubMed ID: 10461057
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of dose intensification with cisplatin and carboplatin plus vindesine in patients with inoperable non-small cell lung cancer.
Nakanishi Y; Takayama K; Kawasaki M; Yatsunami J; Inutsuka S; Wakamatsu K; Tsuruta N; Hara N
Am J Clin Oncol; 1997 Aug; 20(4):393-7. PubMed ID: 9256897
[TBL] [Abstract][Full Text] [Related]
19. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]